

Administration of the First Dose of Palivizumab (Synagis®) in an Inpatient vs Outpatient Setting

Adham Abushukur; Hany Aziz MD, MS;
Betsy Walters Burkey, PharmD, BCPS, BCPPS
Cleveland Clinic

Civic Education
Applied Medicine
Internship Program

Purpose and Hypothesis

- To evaluate how many infants received palivizumab within the system-set metric of 3 business days after discharge in this new workflow between the fall of 2017-spring 2018.
- To compare the time interval between the first and second doses (where the data is available) in the 2016-2017 and 2017-2018 seasons.
- I hypothesize that if the outpatient clinic's workload was reduced by the inpatient care team, then the likelihood of delays in the process of administering palivizumab will be reduced, resulting in a more efficient and cost effective healthcare system.

Methodology




- Collected patient data for all palivizumab recipients through EPIC system from October 2016-April 2018
- Retrospectively analyzed 64 data points per patient
- Compared the efficiency of dose administration between patients from the 2016-2017 RSV season and patients from the 2017-2018 season

Data

- 2016-2017 patients (72 hours prior to discharge):
 - 54 total patients
 - 20 received first dose within guidelines
 - 34 received outside of guidelines
- 2017-2018 patients (3 business days post-discharge):
 - 46 total patients
 - 35 received within guidelines
 - 8 received outside of guidelines
 - 3 unknown date of first dose (first dose taken in PCP)
 - The mean amount of days outside of the guidelines is 10.5 days
- 2016-2017 had 35 patients with multiple doses
- 2017-2018 had 29 patients with multiple doses
- Days in between the first and second dose for 2016-2017 patients ranged from 24-156 days, while 2017-2018 patients ranged from 26-51 days

- Mean days from dose 1 to 2 (2016-2017):
 - 38 (30.37 when outliers were removed)
- Mean days from dose 1 to 2 (2017-2018):
 - 30 (28.51 when outliers were removed)

Results



Conclusions

- The first dose of palivizumab was given in the outpatient clinic. There was an increase in the percentage of patients receiving their first dose inside of the guidelines (from 37% to 76%), as well as a decrease in the amount of days in between the first and second doses that better reflects the guidelines (from 38 days to 30 days or 30.37 to 28.51 normalized).

Recommendations

- Hospitals that address prior authorize the use of palivizumab on the outpatient side should transfer the workload to the inpatient care team
- Larger population size